Presentation of HLA Class I-Derived Peptides: Potential Involvement in Allorecognition and HLA-B27-Associated Arthritis

Immunological Reviews

Volumn , Issue 154, 1996, Pages 137-154

  Parham, Peter ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN; HLA ANTIGEN CLASS 2; PEPTIDE;

ALLOIMMUNITY; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTHRITIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE PREDISPOSITION; IMMUNOLOGY;

ANIMALS; ANTIGEN PRESENTATION; ARTHRITIS; DISEASE SUSCEPTIBILITY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-B27 ANTIGEN; HUMANS; PEPTIDES;

EID: 0030299910     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065x.1996.tb00932.x     Document Type: Article

References (70)

1. Barber, L. D. & Parham, P. (1993) Peptide binding to major histocompatibility complex molecules. Annu. Rev. Cell Biol. 9, 163-206.
2. Barber, L. D., Gillece-Castro, B., Percival, L., Li, X., Clayberger, C. & Parham, P. (1995) Overlap in the repertoires of peptides bound in vivo by a group of related HLA-B allotypes. Curr. Biol. 5, 179-190.
3. Barouch, D., Friede, T., Stevanovic, S., Tussey, L., Smith, K., Rowland-Jones, S., Braud, V., McMichael, A. & Rammensee, H.-G. (1995) HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J. Exp. Med. 182, 1847-1856.
4. Benjamin, R. & Parham, P. (1990) Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol. Today 11, 137-142.
5. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L. & Wiley, D. C. (1987) Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329, 506-512.
6. Breban, M., Hammer, R. E., Richardson, J. A. & Taurog, J. D. (1996a) Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J. Exp. Med. 178, 1607-1616.
7. Breban, M., Fernández-Sueiro, J. L., Richardson, J. A., Hadavand, R. R., Maika, S. D., Hammer, R. E. & Taurog, J. D. (1996b) T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J. Immunol. 156, 794-803.
8. Chen, B. P., Madrigal, A. & Parham, P. (1990) Cytotoxic T cell recognition of an endogenous HLA peptide presented by a class II HLA molecule. J. Exp. Med. 172, 779-778.
9. 2-microglobulin increases the occurrence of ankylosing enthesopathy in HLA-B27 transgenic mice. Clin. Rheumutol. 15, Suppl. 1, 10-12.
10. Clayberger, C., Lyu, S. C., Pouletty, P. & Krensky, A. M. (1993) Peptides corresponding to T-cell receptor-HLA contact regions inhibit class I-restricted immune responses. Transplant. Proc. 25, 477.
11. Clayberger, C., Parham, P., Rothbard, J., Ludwig, D. S., Schoolnik, G. K. & Krensky, A.M. (1987) HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature 330, 763-765.
12. Cucca, F. & Todd, J. A. (1996) HLA susceptibility to type 1 diabetes: methods and mechanisms. In: HLA and MHC Genes, Molecules and Function, (eds. M. Browning & A. McMichael) pp. 383-406. Bios Scientific Publishers, Oxford.
13. 1 helix of the first domain of HLA-B7 01. Transplantation 59, 661-669.
14. D'Amato, M., Fiorillo, M. T., Carcassi, C., Mathieu, A., Zuccarelli, A., Bitti, P. P., Tosi, R. et al. (1995) Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur. J. Immunol. 25, 3199-3201.
15. Davenport, M. P. & Hill, A. V. S. (1996) Peptides associated with class I and class II molecules. In: HLA and MHC Genes, Molecules and Function, (eds. M. Browning & A. McMichael). pp. 277-308. Bios Scientific Publishers, Oxford.
16. Del Porto, P., D'Amato, M., Fiorillo, M. T., Tuosto, M. T., Piccolella, E. & Sorrentino, R. (1994) Identification of a novel HLA-B27 subtype by restriction analusis of a cytotoxic gamma delta T cell clone. J. Immunol. 153, 3093-3100.
17. Ebringer, A., Ahmadi, K., Fielder, M., Rashid, T., Tiwana, H., Wilson, C., Collado, A. & Tani, Y. (1996) Molecular mimicry: the geographic distribution of immune responses to Klebsiella in ankylosing spondylitis and its relevance to therapy. Clin. Rheumatol. 15, Suppl. 1, 57-61.
18. Engelhard, V. H. (1994) Structures of peptides associated with MHC class I molecules. Curr. Biol. 6, 13-23.
19. Falk, K., Rötzschke O, Stevanovic, S., Jung, G. & Rammensee, H. G. (1991) Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 351, 290-296.
20. Feltkamp, T.E.W. (1996) Non-HLA-B27 genetic factors in HLA-B27 associated diseases. Clin. Rheumatol. 15, Suppl. 1, 40-43.
21. Ferrone, S., Yamamura, M., Grosse-Wilde, H. & Pouletty, P. (1992) Summary of the serum-soluble HLA class I component. In: HLA 1991: Proceedings of the Eleventh International Workshop and Conference (eds. K. Tsuji, M. Aizawa & T. Sasazuki), vol.1, pp. 1057-1061. Oxford University Press, Oxford.
22. Goodnow, C. C.(1996) Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad. Sci. U. S. A. 93, 2264-2271.
23. Gregersen, P. K., Silver, J. & Winchester, R. J. (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213.
24. Gumperz, J. E. & Parham, P. (1995) The enigma of the natural killer cell. Nature 378, 245-248.
25. Hall, F. C. & Bowness, P. (1996) HLA and disease: from molecular function to disease association? In HLA and MHC Genes, Molecules and Function (eds. M. Browning & A. McMichael), pp. 353-381. Bios Scientific Publishers, Oxford.
26. 2-m: an animal model of human HLA-B27 associated disorders. Cell 63, 1099-1112.
27. Hermann, E., Yu, D. T. Y., Meyer zum Büschenfelde, K.-H. & Fleischer, B. (1993) HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 342, 646-650.
28. Hilton, R., Lombardi, G. & Lechler, R. (1996) MHC molecules in transplantation and tolerance. In: HLA and MHC Genes, Molecules and Function, (eds. M. Browning & A. McMichael), pp. 407-431. Bios Scientific Publishers, Oxford.
29. Holmes, N. & Parham, P. (1985) Exon shuffling in vivo can generate novel HLA class I molecules. EMBO J. 4, 2849-2854.
30. + patients with ankylosing spondylitis. Arthritis Rheum. 32, 437-445.
31. Jardetzky, T. S., Lane, W. S., Robinson, R. A., Madden, D. R. & Wiley, D. C. (1991) Identification of self peptides bound to purified HLA-B27. Nature 353, 326-329.
32. Keat, A. (1996) Why the joint, why the eye? Clin. Rheumatol. 15, Suppl. 1, 19-21.
33. Khan, M. A. (1995) HLA-B27 and its subtypes in world populations. Curr. Opin. Rheumatol. 1, 263-269.
34. Khan, M. A. (1996) Epidemiology of HLA-B27 and arthritis. Clin. Rheumatol. 15, Suppl. 1, 10-12.
35. 2-microglobulin: a model of human spondylarthropathies. J. Exp. Med. 182, 1153-1158.
36. 1-helix. Clin. Exp. Immunol. 86, 399-404.
37. Liu, Z., Harris, P. E., Colovai, A. I., Reed, E. F., Maffei, A. & Suciu-Foca, N. (1996) Indirect recognition of donor MHC class II antigens in human transplantation. Clin. Immunol. Immunopathol. 78, 228-235.
38. López de Castro, J. A. (1989) HLA-B27 and HLA-A2 subtypes: structure, evolution and function. Immunol. Today 10, 239-246.
39. López de Castro, J. A. (1994) Structure, function and disease association of HLA-B27. Curr. Opin. Rheumatol. 6, 371-377.
40. López de Castro, J. A. (1996) HLA-B27 and HLA-B73 polymorphism and its role on antigenicity, peptide presentation and disease susceptibility. Clin. Rheumatol. 15, Suppl. 1, 67-71.
41. López Larrea, C. L., Sujirachato, K., Mehra, N. K., Chiewslip, P., Isarangkura, D., Kanga, U., Dominguez, O., Coto, E., Pena, M., Setien, F. & Gonzalez-Roces, S. (1995) HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens 45, 169-176.
42. Madden, D. R., Gorga, J. C., Strominger, J. L. & Wiley, D. C. (1992) The three-dimensional structure of HLA-B27 at 2.1Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70, 1035-1048.
43. Maryanski, J. L., Pala, P., Corradin, G., Jordan, B. R. & Cerottini, J. C. (1986) H-2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide. Nature 324, 578-579.
44. Oldstone, M. B. A. (1987) Molecular mimicry and autoimmune disease. Cell 50, 819-820.
45. Parham, P., Adams, E. J. & Arnett, K. L. (1995) The origins of HLA-A,B,C polymorphism. Immunol. Rev. 143, 141-180.
46. Parham, P., Androlewicz, M. J., Brodsky, F. M., Holmes, N. J. & Ways, J. (1982) Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens. J. Immunol. Methods 53, 133-173.
47. Parham, P., Belich, M., Hildebrand, W. H., Little, A.-M., Madrigal, J. & Zemmour, J. (1992) Correlation of serology with the structure of HLA class I molecules. In: HLA 1991: Proceedings of the Eleventh International Workshop and Conference, vol 1. (eds. K. Tsuji, M. Aizawa & T. Sasazuki), pp. 542-559. Oxford Univeersity Press, Oxford.
48. 2 domain of HLA-2. Nature 325, 624-628.
49. 2-microglobulin free HLA class I α-chains on activated T-cells is regulated by internalization, constitutive and protein kinase C inducible release. Tissue Antigens 48, 15-21.
50. Ren, E. C., Koh, W. H., Sim, D., Wee, G. B. & Chan, S. H. (1997) B*2706 is protective for ankylosing spondylitis in Singaporean Chinese. Tissue Antigens 49, 65.
51. + patients. Arthritis Rheum. 32, 1135-1141.
52. Roudier, J., Petersen, J., Rhodes, G. H., Luka, J. & Carson, D. A. (1989) Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 Dr β-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc. Natl Acad. Sci. U. S. A. 86, 5104-5109.
53. Salter, R. D., Clayberger, C., Lomen, C. E., Krensky, A. M. & Parham, P. (1987) In vitro mutagenesis at a single residue introduces B and T cell epitopes into a class I HLA molecule. J. Exp. Med. 166, 283-288.
54. Saper, M. A., Bjorkman, P. J. & Wiley, D. C. (1991) Refined structure of the human histocompatibility antigen HLA-A2 at 2.6Å resolution. J. Mol. Biol. 219, 277-319.
55. Schwimmbeck, P. L., Yu, D. T. Y. & Oldstone, M. B. A. (1987) Autoantibodies to HLA B27 in the sera of HLA-B27 patients with ankylosing spondylitis and Reiter's syndrome. J. Exp. Med. 166, 173-181.
56. Shimuzu, Y. & DeMars, R. (1989) Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J. Immunol. 142, 3320-3328.
57. Simmons, W. A., Leong, L. W. Y., Satumtira, N., Butcher, G. W., Howard, J. C., Richardson, J. A., Slaughter, C. A., Hammer, R. E. & Taurog, J. D. (1996) Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease. J. Immunol. 156, 1661-1667.
58. Stieglitz, H., Fosmire, S. & Lipsky, P. E. (1988) Bacterial epitopes involved in the induction of reactive arthritis. Am. J. Med. 85, 56-58.
59. Suto, R. & Srivastava, P. K. (1996) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269, 1585-1588.
60. Taurog, J. D. & Hammer, R. E. (1996) Experimental spondylarthropathy in HLA-B27 transgenic rats. Clin. Rheumatol. 15, Suppl. 1, 22-27.
61. Taurog, J. D., Maika, S. D., Simmons, W. A., Breban, M. & Hammer, R. (1993) Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J. Immunol. 150, 4168-4178.
62. Taurog, J. D., Richardson, J. A., Croft, J. Simmons, W. A., Zhou, M., Fernández-Sueiro, J. L., Balish, E & Hammer, R. E. (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 180, 2359-2364.
63. Tiilikainen, A., Lassus, A. Karvonen, J. & Julin, M. (1980) Psoriasis and HLA-Cw6. Br. J. Dermatol. 102, 179-184.
64. Tiwari, J. L. & Terasaki, P. I. (1985) HLA and Disease Associations. Springer Verlag, New York.
65. Tzeng, C.-M., Adams, E. J., Gumperz, J. E., Percival, L., Wells, R. S., Parham, P. & Barber, L. D. (1996) Peptides bound endogenously by HLA-Cw*0304 expressed in LCL 721.221 cells include a peptide derived from HLA-E. Tissue Antigens 48, 325.
66. Uksila, J. & Toivanen, P. (1996) HLA-B27 and bacteria. Clin. Rheumatol. 15, Suppl. 1, 44-47.
67. Ulbrecht, M., Kellermann, J., Johnson, J. P. & Weiss, E.H. (1992) Impaired intracellular transport and cell surface expression of nonpolymorphic HLA-E: evidence for inefficient binding. J. Exp. Med. 176, 1083-1090.
68. Ways, J. P., Rothbard, J. B. & Parham, P. (1986) Amino acid residues 56 to 69 of HLA-A2 specify an antigenic determinant shared by HLA-A2 and HLA-B17. J. Immunol. 137, 217-222.
69. Wei, X & Orr, H. T. (1990) Differential expression of HLA-E, HLA-F and HLA-G transcripts in human tissue. Hum. Immunol. 29, 131-139.
70. Yanigasawa, H., Richardson, J. A., Taurog, J. D. & Hammer, R. E. (1995) Characterization of psoriaform and alopecic skin lesions in HLA-B27 transgenic rats. Am. J. Pathol. 147, 955-964.